Martin Shkreli resigns as Turing CEO day after his arrest

TRENTON, N.J. -- The pharmaceutical executive reviled for price-gouging resigned Friday as head of the drugmaker Turing Pharmaceuticals, a day after being arrested on charges of securities fraud related to a company he previously ran.

See Full Article

Martin Shkreli, whose arrest delighted countless people appalled by his unapologetic stance after hiking the price of a life-saving drug by 5,000 per cent, is being replaced on an interim basis by Ron Tilles, according to a statement issued Friday by Turing, which is privately held.

Tilles has been chairman of Turing's board of directors since the company was founded late last year. Turing said that Tilles will continue to hold the board chairman position as well. He has worked at numerous private equity and venture capital firms in the pharmaceutical and medical device industries over the last two decades.

Shkreli, a 32-year-old former hedge fund manager, has become the "most hated man in America," according to some headline writers, for jacking up the price of Daraprim, the only approved drug for a life-saving parasitic infection called toxoplasmosis, from $13.50 to $750 per pill. He did so shortly after Turing acquired rights to sell the pill in the U.S., paying another company $55 million for it.

On Thursday, federal prosecutors said that between 2009 and 2014, Shkreli lost some of his hedge fund investors' money through bad trades, then looted Retrophin, a pharmaceutical company where he was CEO, for $11 million to pay back his disgruntled clients.

Shkreli, a flagrant self-promoter who recently said he should have hiked the price of Daraprim even more, was paraded in handcuffs by the FBI after his arrest. Photos of him, wearing a grey hoodie as he was escorted by authorities, spread on the Internet like wildfire, generating social media posts celebrating his apparent fall. The news -- unrelated to his actions at Turing -- delighted patients, advocacy groups and average Joes who found his price-gouging despicable.

Shkreli pleaded not guilty to charges of securities fraud and conspiracy, which carry a sentence of up to 20 years in prison if he's convicted. He was released on $5 million bail.

Turing, which has offices in New York and Zug, Switzerland, said Tilles has worked with several securities firms, starting with Merrill Lynch in 1985.

In the company's statement, Tilles said he's excited by the chance to guide Turing and that it's "committed to ensuring that all patients have ready and affordable access to Daraprim" and a second drug, Vecamyl, a pill for treating high blood pressure.

Tilles also thanked Shkreli "for helping us build Turing Pharmaceuticals into the dynamic research-focused company it is today," a reference to Shkreli's after-the-fact claim that he needed to raise Daraprim's price so much to fund research on other drugs.

Shkreli recently became the CEO of a second company, KaloBios Pharmaceuticals, Inc., based in South San Francisco, California. There's no word yet on whether he'll remain at the helm there.


Latest Economic News

  • New Wells Fargo CEO to employees: 'We're sorry'

    Economic CTV News
    NEW YORK -- Newly appointed Wells Fargo CEO Tim Sloan told employees Tuesday that he is "sorry for the pain" that the bank's employees have suffered as a result of the company's sales practices scandal. Source
  • Canadian malls need to diversify to become destinations for shoppers, say experts

    Economic CTV News
    MONTREAL -- The rise of online shopping is forcing Canadian malls to diversify and become destinations that offer a range of services including entertainment and sporting venues in addition to traditional clothing stores, a Montreal real estate conference heard Tuesday. Source
  • Quebec says it's on track for $2.2-billion surplus in current fiscal year

    Economic CTV News
    Quebec is projecting a higher than expected surplus of $2.2 billion in the current fiscal year and is also abolishing a health tax two years ahead of schedule. Information available over the summer led the government to call for a surplus of $1.8 billion for fiscal 2016-17, which ends next March 31, but Finance Minister Carlos Leitao said Tuesday that provincial revenues have increased more than expected. Source
  • Pipeline company asks protesters to leave North Dakota land

    Economic CTV News
    CANNON BALL, N.D. - The developer of the Dakota Access oil pipeline said Tuesday that the dozens of protesters who have camped on company-owned land since the weekend are trespassing and that "lawless behaviour will not be tolerated. Source
  • Red ink will rule, but optimism in the oilpatch as earnings released

    Economic CBC News
    Precision Drilling announced some full-on good news last week with its third-quarter earnings. Although the company lost $47 million in the third quarter and revenue was down by nearly a half, it also said that it had rehired 1,000 workers. Source
  • CN Rail slightly raises outlook for 2016 despite dip in Q3 profits, revenues

    Economic CTV News
    MONTREAL -- Canadian National Railway Co. boosted its earnings forecast for 2016 despite seeing its profits and revenues decline in the third quarter. The Montreal-based railway raised it outlook for the year, saying it expects adjusted earnings will increase by about one per cent above the $4.44 per share earned last year. Source
  • CN Rail recalls workers to prepare for the smooth handling of bumper grain crop

    Economic CTV News
    MONTREAL -- Canadian National Railway Co. says it has recalled laid-off employees to handle the start of what is expected to be bumper grain crops in Canada and the United States. "We're handling and ready to handle more of the crop that has been produced," chief operating officer Mike Cory said Tuesday after the Montreal-based carrier reported third-quarter results. Source
  • Former Expos owner, Seagram's titan Charles Bronfman reflects on life as a 'late bloomer'

    Economic CTV News
    He steered Seagram's Co. Ltd. to great success and brought the Montreal Expos to Canada, but Canadian billionaire Charles Bronfman insists he was a "late bloomer," after years of struggling with low self-esteem in his early life. Source
  • iPhone 7 sales, holiday outlook in focus as Apple reports after the bell Tuesday

    Economic CBC News
    Apple Inc. will report fourth-quarter and full-year earnings after the close of trading Tuesday, with analysts expecting the tech giant to report a third straight quarterly revenue drop and its first drop in annual revenue in 15 years. Source
  • Apple iPhone sales drop for 3rd-straight quarter, but still top expectations

    Economic CBC News
    Apple Inc. will report fourth-quarter and full-year earnings after the close of trading Tuesday, with analysts expecting the tech giant to report a third straight quarterly revenue drop and its first drop in annual revenue in 15 years. Source